These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

385 related items for PubMed ID: 11268285

  • 1. Intercellular transfer of the virally derived precursor form of acid alpha-glucosidase corrects the enzyme deficiency in inherited cardioskeletal myopathy Pompe disease.
    Pauly DF, Fraites TJ, Toma C, Bayes HS, Huie ML, Hirschhorn R, Plotz PH, Raben N, Kessler PD, Byrne BJ.
    Hum Gene Ther; 2001 Mar 20; 12(5):527-38. PubMed ID: 11268285
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Glycogen storage in multiple muscles of old GSD-II mice can be rapidly cleared after a single intravenous injection with a modified adenoviral vector expressing hGAA.
    Xu F, Ding E, Migone F, Serra D, Schneider A, Chen YT, Amalfitano A.
    J Gene Med; 2005 Feb 20; 7(2):171-8. PubMed ID: 15515143
    [Abstract] [Full Text] [Related]

  • 8. Recombinant human acid alpha-glucosidase corrects acid alpha-glucosidase-deficient human fibroblasts, quail fibroblasts, and quail myoblasts.
    Yang HW, Kikuchi T, Hagiwara Y, Mizutani M, Chen YT, Van Hove JL.
    Pediatr Res; 1998 Mar 20; 43(3):374-80. PubMed ID: 9505277
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Retroviral transfer of acid alpha-glucosidase cDNA to enzyme-deficient myoblasts results in phenotypic spread of the genotypic correction by both secretion and fusion.
    Zaretsky JZ, Candotti F, Boerkoel C, Adams EM, Yewdell JW, Blaese RM, Plotz PH.
    Hum Gene Ther; 1997 Sep 01; 8(13):1555-63. PubMed ID: 9322088
    [Abstract] [Full Text] [Related]

  • 11. Enhanced efficacy of an AAV vector encoding chimeric, highly secreted acid alpha-glucosidase in glycogen storage disease type II.
    Sun B, Zhang H, Benjamin DK, Brown T, Bird A, Young SP, McVie-Wylie A, Chen YT, Koeberl DD.
    Mol Ther; 2006 Dec 01; 14(6):822-30. PubMed ID: 16987711
    [Abstract] [Full Text] [Related]

  • 12. Correction of glycogen storage disease type II by enzyme replacement with a recombinant human acid maltase produced by over-expression in a CHO-DHFR(neg) cell line.
    Martiniuk F, Chen A, Donnabella V, Arvanitopoulos E, Slonim AE, Raben N, Plotz P, Rom WN.
    Biochem Biophys Res Commun; 2000 Oct 05; 276(3):917-23. PubMed ID: 11027569
    [Abstract] [Full Text] [Related]

  • 13. Isolation and characterisation of a recombinant, precursor form of lysosomal acid alpha-glucosidase.
    Fuller M, Van der Ploeg A, Reuser AJ, Anson DS, Hopwood JJ.
    Eur J Biochem; 1995 Dec 15; 234(3):903-9. PubMed ID: 8575451
    [Abstract] [Full Text] [Related]

  • 14. Replacing acid alpha-glucosidase in Pompe disease: recombinant and transgenic enzymes are equipotent, but neither completely clears glycogen from type II muscle fibers.
    Raben N, Fukuda T, Gilbert AL, de Jong D, Thurberg BL, Mattaliano RJ, Meikle P, Hopwood JJ, Nagashima K, Nagaraju K, Plotz PH.
    Mol Ther; 2005 Jan 15; 11(1):48-56. PubMed ID: 15585405
    [Abstract] [Full Text] [Related]

  • 15. Fully deleted adenovirus persistently expressing GAA accomplishes long-term skeletal muscle glycogen correction in tolerant and nontolerant GSD-II mice.
    Kiang A, Hartman ZC, Liao S, Xu F, Serra D, Palmer DJ, Ng P, Amalfitano A.
    Mol Ther; 2006 Jan 15; 13(1):127-34. PubMed ID: 16169280
    [Abstract] [Full Text] [Related]

  • 16. Antibody-mediated enzyme replacement therapy targeting both lysosomal and cytoplasmic glycogen in Pompe disease.
    Yi H, Sun T, Armstrong D, Borneman S, Yang C, Austin S, Kishnani PS, Sun B.
    J Mol Med (Berl); 2017 May 15; 95(5):513-521. PubMed ID: 28154884
    [Abstract] [Full Text] [Related]

  • 17. Correction of glycogenosis type 2 by muscle-specific lentiviral vector.
    Richard E, Douillard-Guilloux G, Batista L, Caillaud C.
    In Vitro Cell Dev Biol Anim; 2008 May 15; 44(10):397-406. PubMed ID: 18810562
    [Abstract] [Full Text] [Related]

  • 18. Correction of glycogen storage disease type II by an adeno-associated virus vector containing a muscle-specific promoter.
    Sun B, Zhang H, Franco LM, Brown T, Bird A, Schneider A, Koeberl DD.
    Mol Ther; 2005 Jun 15; 11(6):889-98. PubMed ID: 15922959
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Synergistic Efficacy from Gene Therapy with Coreceptor Blockade and a β2-Agonist in Murine Pompe Disease.
    Han SO, Li S, Bird A, Koeberl D.
    Hum Gene Ther; 2015 Nov 15; 26(11):743-50. PubMed ID: 26417913
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.